Several clinical trials have shown the superiority of autologous stem cell transplantation over conventional dose therapy for patients with multiple myeloma. This treatment, however, is limited to younger patients (o65 years) owing to concerns about toxicity and treatmentrelated mortality (TRM) in older patients. We treated 26 elderly myeloma patients (470 years), who received a preparative regimen of melphalan 200 mg/m 2 (19 patients), melphalan 180 mg/m 2 (six patients) or melphalan 140 mg/m 2 (one patient). Twenty-two of the 26 patients were alive after a median follow-up of 25 months (range ¼ 8-74). Responses (complete þ partial response) were seen in 20 patients (77%), five (19%) of which were complete responses. Median PFS was 24 months, whereas median OS has not been reached. Cumulative incidence of 100-day TRM was 0%. Three-year PFS and OS were 39% (range ¼ 16-61) and 65% (range ¼ 35-83), respectively. A low serum albumin (o3.5 g/dl) was associated with a shorter PFS (P ¼ 0.02). Patients with relapsed disease at transplant, and an interval of 412 months between diagnosis and autotransplant, had a shorter OS (P ¼ 0.0004 and 0.04). HDT and autologous transplant is safe and feasible in elderly myeloma patients.
Background
Approximately 15 000 patients in the US are diagnosed with multiple myeloma each year, and about half of them are over 70 years of age. The median survival for multiple myeloma varies from 3 to 4 years. 1 The treatment of myeloma ranges from conventional therapy to high-dose therapy followed by autologous or allogeneic hematopoietic stem cell transplantation (HSCT). 2 Several randomized trials have shown that autologous HSCT is associated with superior complete remission (CR) rates, event-free survival (EFS) and overall survival (OS). [3] [4] [5] [6] [7] Traditionally autologous HSCT are restricted to patients o70 years of age owing to concerns about excessive toxicity and the presence of comorbid conditions in older patients. 8, 9 However, two previous reports have shown that age alone is not an exclusion criterion for autologous HSCT as long as patients fulfill other eligibility criteria. 10, 11 High-dose melphalan at a dose of 200 mg/m 2 is accepted as the most effective conditioning regimen. 12 However, this regimen is associated with a higher treatment-related mortality (TRM) in elderly patients. 11 With greater experience and better supportive care, it would be reasonable to offer this treatment to older patients.
In this study, we analyzed the safety and efficacy of a single autologous HSCT after a preparative regimen of high-dose melphalan in patients older than 70 years at the time of transplant.
Methods

Patients
In this retrospective analysis we studied 26 patients X70 years of age, who received high-dose melphalan and a single autograft transplant at our institution between July 1999 and October 2005. To be eligible for an autotransplant, patients had to have acceptable cardiac (left ventricular ejection fraction (LVEF)450%), pulmonary (diffusion capacity for carbon monoxide (DLCO)450%) and hepatic (transaminaseso3 Â upper limit of normal) functions. All patients signed institutional review board (IRB)-approved informed consents for high-dose therapy and autologous transplant.
The response to induction therapy was as follows: 16 patients (61%) had a partial remission (PR); two patients (8%) had minimal response; six patients (23%) had no response (NR); and two patients (8%) had progressive disease. 13 Cytogenetic studies by conventional karyotypic analysis were available in all 26 patients, and showed clonal chromosomal abnormalities in five patients only, whereas the other 21 patients had a normal karyotype. Three patients had hyperdiploidy, one patient had deletion of the short arm of chromosome 1 [del (1) (p22)], and another patient had t(X; 4). None of the 26 patients had previously been treated with melphalan. Melphalan dose was selected by the bone marrow transplantation (BMT) attending physician based on the patient's performance status, comorbidities and tolerance to prior chemotherapy. Melphalan was infused over 30 min in two divided doses over two consecutive days. Unmanipulated autografts were infused 48 h later. All patients received granulocyte colony-stimulating factor (G-CSF), 5 mg/kg/day, from day þ 1 until the absolute neutrophil count (ANC) was 0.5 Â 10 9 /l for two consecutive days, in accordance with our departmental guidelines. Oral levofloxacin, acyclovir and fluconazole were given for the duration of neutropenia. Blood products were given for hemoglobin, o8 g/dl, and platelets, o20 Â 10 9 /l. Peripheral blood stem cells were collected following G-CSF alone in 20 patients, and chemotherapy þ G-CSF in six patients.
Treatment
Statistical methods
Actuarial rates of OS and progression-free survival (PFS) were estimated by the Kaplan-Meier method. PFS and OS were estimated from the time of autotransplant to progression or death. Prognostic factors for survival were evaluated using Cox's proportional hazards model for univariate analyses. Multivariate analysis was not performed owing to a small sample size. Statistical significance was defined at the 0.05 level. Analysis was performed using 
Response criteria
The European Group for Blood and Marrow Transplantation (EBMT) response criteria were used to define CR, partial response (PR) and relapse. 13 CR was defined as the absence of original monoclonal protein in urine and serum by immunofixation, o5% plasma cells in marrow aspirate, and no increase in the size or number of lytic bony lesions. Progressive disease was defined as one of the following: (1) 425% increase in serum or urine monoclonal protein, or plasma cells in the bone marrow and (2) increase in the size or number of lytic bony lesions. 13 
Comorbidity indices
Charlson comorbidity index (CCI) and Seattle's hematopoietic cell transplantation-specific comorbidity index (HCT-CI) were used to score the comorbidities. [15] [16] [17] According to CCI, 17/26 (65%) patients had a CCI score of 0, whereas 13/26 (50%) had a HCT-CI of 0. 18 all patients had stage II (61%) or III disease (38%) at diagnosis. We used ISS because it is a validated staging system, and because of the universal availability of b2 microglobulin and albumin levels at the time of diagnosis. Before the start of preparative regimen, 12 patients were receiving first remission consolidation, seven had primary refractory disease and seven had relapsed disease. Five patients (19%) had a clonal cytogenetic abnormality (42 abnormal metaphases) at the time of transplant. Three patients (11%) had elevated serum creatinine above the upper limits of normal (1.5 mg/dl).
Results
Patients
Stem cell mobilization and engraftment Twenty (77%) patients were mobilized with G-CSF 10 mg/kg/ day alone. Six (23%) patients with high tumor burden received chemotherapyþG-CSF 10 mg/kg/day, with a modified cyclophosphamide, vincristine, adriamycin, dexamethasone (CVAD) regimen to achieve cytoreduction and mobilization. 
Treatment-related toxicity
Five patients were transplanted in the outpatient setting. Only two patients (8%) had grade III to IV nonhematological toxicities (hypoxia, fever). Grade II toxicity, consisting of mucositis, nausea, vomiting and diarrhea, was (Figure 1) . On univariate analysis, a low serum albumin level at transplant (o3.5 g/dl) had a significantly negative impact on PFS (hazards ratio (HR) ¼ 5.5, P ¼ 0.02) ( Table 2) . Patients with relapsed disease at transplant, and patients with an interval of 41 year between diagnosis and transplant had a shorter OS (P ¼ 0.0004 and 0.04, respectively) ( Table 2 ). ISS stage, b2 microglobulin level, lactic dehydrogenase (LDH) level, abnormal cytogenetics, CCI or HCT-CI at the time of transplant did not have any significant impact on OS ( Table 2) .
Discussion
Previous studies have shown that autotransplants can be safely performed in older patients with multiple myeloma, although they are mostly restricted to patients below 70 years of age. [20] [21] [22] [23] [24] There have been a few reports of HDT in patients over 70 years old. 10, 11 In one of those studies, the melphalan dose was reduced to 140 mg/m 2 because a dose of 200 mg/m 2 was associated with higher toxicity and TRM. 11 There have been concerns that older patients may not mobilize well with growth factors. We were able to mobilize an adequate number of CD34 þ cells by G-CSF alone in 77% of patients. The number of CD34 þ cells mobilized and the time to neutrophil and platelet engraftment were comparable with our experience in younger myeloma patients undergoing HDT. 25 The main non-hematological toxicities were nausea, vomiting, diarrhea and mucositis. The treatment was well tolerated and not a single patient died of transplant-related causes in the first 100 days. A higher melphalan dose was not associated with an increase in TRM. All patients had adequate vital organ function before transplant. We also assessed their comorbidity scores before transplant, and 465% of patients had low comorbidity scores according to HCT-CI and Charlson criteria. [15] [16] [17] Overall, 77% of patients achieved CR or PR, which was comparable to the historical controls. The CR rate was 19%, comparable to the 20% reported by Badros et al.
11 in a single autotransplant study. CR rates, especially following strict response criteria, have varied from 20 to 40% in previous reports. In the IFM90 trial, 3 the CR rate was 22%, and the recently reported S9321 trial, 7 the CR rate was 17%. Our results were comparable to those earlier reports. This study highlights the fact that high-dose melphalan can be safely administered to selected patients 470 years old with acceptable toxicity.
After a median follow-up of 25 months, median PFS was 24 months and the median OS has not been reached. Eleven patients with disease progression after autotransplant received various salvage regimens that may have favorably impacted the OS. A recent report from Facon et al. 26 showed superior median EFS (29 vs 19 months) and OS (456 vs 30.5 months) with the standard dose combination of melphalan, prednisone and thalidomide (MPT), than with a high-dose approach using melphalan 100 mg/m 2 Â 2. Although our report is a retrospective analysis, and our approach to mobilization and preparative regimen differs significantly from that study, we note that 100-day TRM was 0% in our report, compared with 7% reported in the Facon study. The MPT combination appears promising, but is associated with significant morbidity, and its encouraging results have to be validated in further randomized trials with a longer follow-up. A preliminary evaluation of prognostic factors showed that a low serum albumin level at autotransplant was the only factor adversely impacting the PFS. It is a well established adverse prognostic factor that also constitutes one of the two factors used in the ISS. 18 As reported by others, the presence of relapsed disease and an interval of greater than 1 year between diagnosis and transplant predicted a shorter OS.
27 b2 microglobulin, an established prognostic marker, did not emerge as an adverse prognostic factor. This may be because b2m loses its significance in older populations, or owing to the small number of observations. Elevated serum LDH, use of thalidomide before autotransplant, and the interval between diagnosis and transplant were some of the other factors that were analyzed but did not emerge as significant predictors of outcome. 28 In summary, high-dose therapy with melphalan 200 mg/ m 2 and autologous transplant is safe and feasible in selected elderly patients with myeloma. Patients with low serum albumin are at a higher risk of early progression, and patients treated in first remission or primary refractory disease survive longer than the patients treated in relapse.
